(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 11.66%
@ $7.86
Utstedt: 14 feb 2024 @ 21:07
Avkastning: -27.82%
Forrige signal: feb 14 - 18:00
Forrige signal:
Avkastning: 1.62 %
Live Chart Being Loaded With Signals
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases...
Stats | |
---|---|
Dagens volum | 1.57M |
Gjennomsnittsvolum | 1.95M |
Markedsverdi | 466.27M |
EPS | $0 ( 2024-05-03 ) |
Neste inntjeningsdato | ( $-0.650 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.81 |
ATR14 | $0.0110 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-02 | Lucera Erick | Buy | 25 966 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 35 300 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 106 000 | Stock Option (right to buy) |
2024-03-02 | Burkly Linda | Buy | 15 055 | Common Stock |
2024-03-02 | Burkly Linda | Buy | 74 400 | Stock Option (right to buy) |
INSIDER POWER |
---|
88.63 |
Last 95 transactions |
Buy: 4 455 498 | Sell: 157 736 |
Volum Korrelasjon
Editas Medicine Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BROG | 0.916 |
HUGE | 0.915 |
RKDA | 0.906 |
WKHS | 0.899 |
PYCR | 0.898 |
CDZI | 0.897 |
MIRM | 0.895 |
JWEL | 0.888 |
NVIV | 0.886 |
BLRX | 0.87 |
10 Mest negative korrelasjoner | |
---|---|
RNLC | -0.876 |
BCOR | -0.876 |
EBACU | -0.872 |
JNCE | -0.868 |
EGLE | -0.865 |
HPLTU | -0.864 |
IVCB | -0.862 |
TZPSU | -0.862 |
MSSA | -0.86 |
GOOGL | -0.856 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Editas Medicine Inc Korrelasjon - Valuta/Råvare
Editas Medicine Inc Økonomi
Annual | 2023 |
Omsetning: | $78.12M |
Bruttogevinst: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2023 |
Omsetning: | $78.12M |
Bruttogevinst: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2022 |
Omsetning: | $19.71M |
Bruttogevinst: | $13.38M (67.85 %) |
EPS: | $-2.98 |
FY | 2021 |
Omsetning: | $25.54M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.85 |
Financial Reports:
No articles found.
Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.